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Gene dosage by real-time quantitative PCR has proved to be accurate for measuring gene copy number. The aim of this study was
to apply this approach to the CYP2D6 gene to allow for rapid identiﬁcation of poor and ultrarapid metabolizers (0, 1, or more
than 2 gene copy number). Using the 2−∆∆Ct calculation method and a duplex reaction, the number of CYP2D6 gene copies was
determined. Quantitative PCR was performed on 43 samples previously analyzed by Southern blotting and long PCR including 20
samples with a heterozygous deletion, 11 with normal copy number (2 copies), and 12 samples with duplicated genes. The average
ratio ranged from 1.02 to 1.28, 1.85 to 2.21, and 2.55 to 3.30, respectively, for the samples with 1 copy, 2 copies, and 3 copies. This
study shows that this method is sensitive enough to detect either a heterozygous gene deletion or duplication.
INTRODUCTION
Today a variety of assays are available for the quan-
tiﬁcation of CYP2D6 copy number including Southern
blotting, long PCR, DNA invader system [1], and, more
recently, TaqMan technology [2]. Southern blotting and
long PCR require a large amount of genomic DNA and
are costly in terms of reagents, work, and time. More-
over long PCR does not allow for the determination of
the exact copy number. To date, real-time quantitative
PCR has been widely used to quantify viral copy num-
ber, to perform gene expression studies, to diagnose ge-
netic diseases, and to quantify gene copy number in
transgenic animals, or to measure oncogene ampliﬁca-
tion in tumor cells [3]. Indeed, many gene deletions or
duplications are responsible for genetic disorder and are
now diagnosed by quantitative PCR, such as Charcot-
Marie-Tooth I, hereditary neuropathy with liability to
pressure palsies [4, 5], proximal spinal atrophy [6], α-
thalassemia [7], and down syndrome [8]. Moreover, gene
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dosage of xenobiotic-metabolizing enzymes has already
been applied for glutathione S-transferases [9].
Very recently Schaeﬀeler et al successfully developed
TaqMan probes for the determination of CYP2D6 copy
number [2]. Because of the larger number of allelic vari-
ants among CYP2D6 and the presence in tandem of two
inactive pseudogenes (CYP2D8 and CYP2D7), the choice
for the localization of the target sequence has become
complex.Inaddition,itisnecessarytotakeintoaccountat
the same time the sequence speciﬁcity and the constraints
requiredfortheTaqManprobes.Schaeﬀeleretalvalidated
their technique by including 64 samples but with one lim-
itationintheCYP2D6probe.Thus,aSNPislocatedinthe
target sequence, which leads to an undetermined geno-
type among Asian subjects carrying the CYP2D6∗10 and
∗36 alleles.
In this study, a new real-time duplex PCR has been
developed, allowing for the determination of the CYP2D6
gene copy number for every sample since no SNP was de-
scribedinourtargetsequence.First,TaqManMGBprobes
were used to improve the speciﬁcity of the reaction. Sec-
ond, the duplex strategy allowed for the coampliﬁcation
of CYP2D6 and the referent gene (RNase P) in the same
well, which increases reproducibility and decreases the
analysis cost.
For this purpose, CYP2D6 copy number was deter-
mined by the comparative Ct method [10]i n4 3s u b -
jects, distributed as follows: 12 duplicated, 20 deleted, and
11 with two copies. The determination of CYP2D6 copy
number by real-time quantitative PCR was then validated
from previous long PCR/Southern blotting results [11].2005:3 (2005) CYP2D6 Gene Copy Number by Real-Time Quantitative PCR 249
Table 1. CYP2D6 genotype of the samples included in this
study.
CYP2D6 copy Number of CYP2D6 genotype
number samples
9C Y P 2 D 6 ∗1/∗5
3C Y P 2 D 6 ∗2/∗5
13 C Y P 2 D 6 ∗2B/∗5
3C Y P 2 D 6 ∗4A/∗5
2 Unknowna
3C Y P 2 D 6 ∗2/∗2
3C Y P 2 D 6 ∗2/∗2B
22 C Y P 2 D 6 ∗2/∗1
2C Y P 2 D 6 ∗4 ×2/∗5b
1 Unknownc
3d
3C Y P 2 D 6 ∗1/∗1
3C Y P 2 D 6 ∗1/∗2
1C Y P 2 D 6 ∗1/∗9
1C Y P 2 D 6 ∗1/∗4
1C Y P 2 D 6 ∗1/∗2d
1C Y P 2 D 6 ∗1/∗28
1C Y P 2 D 6 ∗1/∗2B
1 Unknownc
aCarrier of heterozygous CYP2D6∗5 (deletion) and other
uncharacterized alleles.
bCarrier of both deletion and duplication of CYP2D6 resulting in two
ﬁnal copies of the CYP2D6 gene.
cUndetermined genotype, Southern blot, and long PCR only.
dSamples with the CYP2D6∗2 ×2, corresponding to the duplication.
MATERIALS AND METHODS
DNAsamples
DNA samples were obtained from a case/control
study where CYP2D6 gene deletion and/or duplica-
tion had been previously investigated by long PCR
and Southern blotting [11]. DNA was prepared us-
ing standard methodology with proteinase K, extracted
by phenol-chloroform, and precipitation with absolute
ethanol [11]. DNA samples were stored at −20◦C. The
DNA concentration was determined by optical density
at 260nm. All samples (except 4) were previously geno-
typed for CYP2D6 alleles [12]( Table 1). However for
these DNA samples, Southern blotting analysis and long
PCR were available. For the deﬁnition of alleles, see
http://www.imm.ki.se/CYPalleles/cyp2d6.htm.
Sequencing
Sequencing was performed on the ABI Prism
9700 Genetic Analyzer System (Applied Biosystems,
Courtabœuf, France). Five µL of puriﬁed PCR prod-
uct (enzymatic puriﬁcation with ExoSap kit, Amersham
Biosciences, Orsay, France) was mixed with 5µLo fs e -
quencemixcontaining1µLofthesameforwardorreverse
p r i m e r su s e df o rP C Ra n d4µL of BDT (DNA sequencing
kit, big dye terminator cycle sequencing; Applied Biosys-
tems).Asequencereactionwasthenperformed.Sequenc-
ing products were puriﬁed before analysis as indicated by
the manufacturer.
Probeandprimerdesign
Genomic sequences of CYP2D6 (GenBank accession
no M33388) and CYP2D7/8 (GenBank accession no
M33387) were used to generate the speciﬁc target se-
quence [13]. Primer Express software version 1.0( A p -
plied Biosystems) was used with manual adjustment to
design a set of primers and probe which are speciﬁc to
CYP2D6gene.Forthedetectionofgenecopynumber,the
position and length of hybridization probes and primers
were optimized by using BLAST program and TaqMan
MGB probes. Sequences for the TaqMan MGB probe and
PCR primers are listed in Figure 1. The size of the PCR
product for CYP2D6 was 78bp. Primers and probe for
the RNase P were obtained as TaqMan endogenous con-
trol kits (Applied Biosystems) (sequence and size of PCR
product not provided by the manufacturer). Finally, the
CYP2D6 probe was labeled at the 5  end with FAM, the
RNase P was labeled at 5  end with VIC, and both probes
had a nonﬂuorescent quencher.
Quantitativereal-timePCRconditions
Gene dosage analysis was performed in a quantitative
duplex PCR assay. The following reagents were used for
ampliﬁcation in 20µL:5 µL of DNA (around 100ng),
300nM of each CYP2D6 primer, 10µLo fM a s t e rM i x
(2X),250nMofCYP2D6probe,1µLofRNasePkit(20X)
andﬁnalvolumewasadjustedwithsterilewater.Thether-
mal cycling conditions were ﬁrst 2minutes at 50◦Ca n d
10minutes at 95◦C and consisted of 40 cycles at 95◦C
for 15seconds and 60◦C for 1minute. The PCR was per-
formedina384-wellclearopticalreactionplate7900(Ap-
plied Biosystems).
Genedosageanalysis
The RNase P gene was coampliﬁed with the CYP2D6
gene and served as an internal standard (two copies
present in subject with or without duplication/deletion
of the CYP2D6 gene). The strategy is based on the rela-
tive quantiﬁcation of the target sequence (CYP2D6) and
a reference sequence (RNase P) and requires that the
PCR eﬃciencies of the CYP2D6 gene and the RNase P
PCR reactions be close to the identical. For TaqMan PCR
calibration, we selected DNA samples from six control
individuals with two copies of the CYP2D6 (ie, indi-
viduals previously characterized by Southern blotting
and long PCR). During the log-linear phase, ampliﬁca-
tion can be described by N = No(1 + E)n,w h e r eN
is the number of ampliﬁed molecules, No is the ini-
tial number of molecules, E is the ampliﬁcation eﬃ-
ciency, and n is the number of cycles. If the ampliﬁcation250 Laurent Bodin et al 2005:3 (2005)
GGTGTCCCAGCAAAGTTCATGGGCCCCCGCCTGTACC
Forward primer
CTTCCTCCCTCGGCCCCTGCAC
Probe
TGTTTCCCAGATGGGCTCA
Reverse primer
Figure 1. Probe and primer design. The forward and reverse primers, as well as the probe, were drawn using the Primer Express
software. The target sequence is located in intron 6. The forward primer has a temperature of 58◦C for a length of 19 bases including 4
discriminating ones (in bold) for the CYP2D6 gene related to the CYP2D7/8 sequences; the reverse primer has a temperature of 58◦C
for a length of 21 bases, including 3 nucleotides speciﬁc to the CYP2D6 gene (in bold). The MGB probe corresponds to the sequence
framed on the diagram with one discriminating nucleotide (in bold). The G base (in bold) is another discriminating nucleotide
present in the amplicon.
eﬃciency is similar for the two reactions, the initial con-
centration of the sample is calculated on the basis of
the above formula by using the comparative delta Ct
method as described by Livak et al [10] and the gene copy
number was given by the formula 2−(∆∆Ct+/−SD),w h e r e
∆∆Ct = (Ct RNase Pcalibrator − Ct CYP2D6calibrator) −
(Ct RNase Psample − Ct CYP2D6sample) .AC ti sd e ﬁ n e da s
the point at which the ﬂuorescence level rises above a
baseline. The eﬀect of DNA concentration on PCR ef-
ﬁciency was determined using a control DNA in a di-
lution series from 25, 12.5, 6.25, and 3.125ng per re-
action. The primer concentration for the CYP2D6 gene
was titrated from a 3-by-3 primer matrix (eg, combina-
tions of 100, 300, and 900nM of each forward and reverse
primer).
All the experiments, which involved 11 samples with
2 copies of CYP2D6, 20 with a heterozygous deletion, and
12 with a duplication, were performed three times, and
in each experiment the samples were analyzed in tripli-
cate.
Data were collected and analyzed using sequence de-
tection system software (version 2.0;AppliedBiosystems).
Ampliﬁcation plots were reviewed after performing and
the baseline setting was adjusted manually between 3 to
18 cycles. Reaction wells with PCR reaction failure were
excluded from further data analysis according to Grubbs’s
test. Thus, the analysis was performed with at least two
ampliﬁcation results (duplicate).
RESULTS AND DISCUSSION
Assessmentofassayspeciﬁcity
T h eﬁ r s ts t e po ft h i ss t u d yw a st od e s i g np r i m e r sa n d
probe highly speciﬁc to the CYP2D6 gene and to avoid
coampliﬁcation of pseudogenes. The PCR MGB probes
used here allow for a discriminative quantiﬁcation of the
CYP2D6 gene related to the CYP2D7/8 gene. Because
of their higher melting temperature, they are more sen-
sitive than conventional probes, that is, they create less
background noise and oﬀer greater speciﬁcity. The region
that was chosen for the target sequence was located at in-
tronic sequence of the CYP2D6 gene (intron 6). No SNP
has been reported to be located within this region accord-
ing to the databases (NCBI). Previously, Schaeﬀeler et al
designed CYP2D6 probe that cannot be used with Asian
subjects carrying the CYP2D6∗10 and ∗36 alleles. The
method that is presented here is an alternative method
for the determination of CYP2D6 copy number. Thus,
the above indetermination was avoided. The availability
of two validated methods would be useful for the routine
determination of CYP2D6 gene copy number especially
when checking that a result is necessary or when genotyp-
ing Asian individuals.
Speciﬁcity for CYP2D6 ampliﬁcation depends on the
sequences of the two primers and the probe, which con-
tained 7 and 1 discriminating nucleotides, respectively
(Figure 1). The ampliﬁcation product was sequenced.
Moreover, to assess the speciﬁcity of the reaction, an as-
say was performed with a DNA sample from a subject
homozygous for the CYP2D6 deletion gene (data not
shown). The copy number of CYP2D6 calculated from
the diﬀerence in Ct values between CYP2D6 and RNase
P corresponded, for this individual, to a value lower than
0.05 copies. These results demonstrated that both sets of
primers and probe were highly speciﬁc to the CYP2D6
gene.
The sequences of CYP2D6 and RNase P gene were
coampliﬁed within the same tube with variable amounts
of genomic DNA (25, 12.5, 6.25, and 3.125ng, resp).
When the Ct values of CYP2D6 and RNase P were plotted
versus DNA amounts, the PCR eﬃciency could be calcu-
lated for each gene in the multiplex based on the slope of
thelinesusingtheformula10−1/slope−1.Thecalculatedef-
ﬁciencies were similar, yielding to values of 0.82 and 0.80,
respectively, for CYP2D6 and RNase P, indicating that the
2−∆∆Ct calculationwasvalid.Moreover,novariationswere
observed in the diﬀerence of Ct values between the target
gene and the reference gene, demonstrating that the DNA2005:3 (2005) CYP2D6 Gene Copy Number by Real-Time Quantitative PCR 251
Table 2. Global analysis of CYP2D6 gene quantiﬁcation based on three independent experiments. The analysis of gene copy number
was performed using the formula 2∗2−∆∆Ct+/−SD. SD stands for standard deviation and CV coeﬃcient of variation. The three groups
are signiﬁcantly diﬀerent with P<. 05 (Mann-Whitney U test). Means are obtained from the averages of the ﬁnal results of each run
after 2∗2−∆∆Ct+/−SD calculation. The borderlines are well delimited in I, II, and III. Means are given by the averages of the results from
each group. Range is deﬁned by the lower and upper limits for each group. SD is the average of sd of the mean of the triplicate.
Number of Expected copy Global mean value of Number of assay Mean value ± SD of Range
patients number∗ CYP2D6 copy∗∗ CYP2D6 copy∗∗
I1 .10 ±0.18 0.76–1.57
20 11 .14 II 1.20 ±0.12 1.04–1.47
III 1.12 ±0.10 0.95–1.33
I1 .87 ±0.17 1.60–2.17
11 21 .99 II 2.09 ±0.18 1.82–2.45
III 2.03 ±0.17 1.86–2.31
I2 .87 ±0.39 2.38–3.57
12 32 .86 II 2.91 ±0.23 2.64–3.26
III 2.80 ±0.30 2.41–3.40
∗ The values obtained after Southern blotting and long PCR.
∗∗ The values obtained calculated from real-time quantitative PCR.
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Figure 2. Multiplex and the 2−∆∆Ct method validation: determi-
nation and comparison of the PCR eﬃciency for each gene. The
straightside(dottedline)ofthePCRofthereferentgene(RNase
P) with a slope =− 3.9( e g ,E = 80%). The straight side (contin-
uous line) of the PCR of the CYP2D6 gene with a slope =− 3.8
(eg, E = 82%). After optimizing in simplex (matrix of primers)
and carrying out a limitation of primers, this graph shows, on
the one hand, that the eﬀectiveness of each PCR is practically
identical and, on the other hand, that the use of the ∆∆Ct calcu-
lation method is validated. Variable amounts of genomic DNA,
25,12.5,6.25,and3.125ng,respectively,wereusedtodrawthese
curves.
concentration was not a critical parameter in this method
(multiplex validation) (Figure 2).
ValidationofthequantitativePCR
In each experiment, the quantitative results of real-
time PCR agreed with those of the reference methods
(Southern blotting and long PCR) from 11 samples with
two copies (including the six samples used as calibrators),
20 samples with 1 copy, and 12 samples with 3 copies. No
overlap between the value range corresponding to each
group(1,2,3copiesofCYP2D6gene)wasobserved.Table
2 includes the average of three independent assays, where
the copy number of the deleted, normal, and duplicated
∗∗∗ ∗∗∗
01 23
Theoretical number of CYP2D6 gene copies
0
1
2
3
4
C
Y
P
2
D
6
c
o
p
y
n
u
m
b
e
r
∗
One copy
Two copies
Three copies
Figure 3. Global analysis of CYP2D6 gene quantiﬁcation in
44 DNA samples based on three independent experiments. The
analysis of gene copy number was performed using the formula
2∗2−∆∆Ct+/−SD. The three groups are signiﬁcantly diﬀerent with
P<. 001 (ANOVA). Means are realized from the averages of the
ﬁnal results of each run after 2∗2−∆∆Ct+/−SD calculation. ∗ de-
notes gene copy number after Southern blotting and long PCR
analysis.
samples was signiﬁcantly separated with P<. 05. As
shown in Figure 3 the mean values of gene quantiﬁcation
data into the three groups 1, 2, and 3 of CYP2D6 gene
were 1.14 (range: 1.02–1.29), 1.99 (range: 1.84–2.21), and
2.86 (range: 2.55–3.30), respectively, in the subjects carry-
ing 1, 2, or 3 copies of the CYP2D6 gene (resp, P<. 001,
ANOVA). These experiment results could be interpreted
properly because boundaries did not overlap. Figure 4 il-
lustrates representative examples of real-time PCR results
for CYP2D6 quantiﬁcation.252 Laurent Bodin et al 2005:3 (2005)
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Figure 4. Ampliﬁcation plots of CYP2D6 and RNase P genes.
The ∆Rn (reﬂecting the quantity of ﬂuorescent probe degraded)
is plotted versus cycle number. (a) Samples with 2 copies of
CYP2D6. In (c) samples with a duplication, the Ct value of
CYP2D6decreasedcomparedtoRNasePwhereasin(b)samples
with deletion, the Ct value of CYP2D6 increased compared to
RNase P.
VariabilityofthequantitativePCR
The reproducibility of these experiments is reﬂected
bythecoeﬃcientofvariation(CV).Alldatawerereported
as the mean, SD, and CV of the average from the results
of three diﬀerent assays. The intra-assay reproducibility
was determined from triplicate measurements within the
same run and the mean of CV for the three experiments
was comprised between 7.1% and 8.9% (data not shown).
The interassay variation ranged from 1.50% to 22% for
the heterozygous deletion samples, from 2.6% to 19% for
the 2 copy samples, and from 3% to 15% for the du-
plicated samples indicating an acceptable level of repro-
ducibility and allowing for discrimination between the
diﬀerent groups. However, a careful examination of the
results showed that the mean of gene dosage for the three
groups was distinct although some values could be close.
Indeed, in the ﬁrst assay (experiment I in Table 2), the
upper range of the one-gene copy group is very close to
the lower range of the two-gene copy group (1.57 and
1.60,resp).Fortheseresults,theintra-assaywasover20%,
strongly suggesting the necessity for low intra-assay vari-
ation to avoid misclassiﬁcation and minimize indetermi-
nation.
CONCLUSION
Compared to other methods (Southern blotting, long
PCR), quantitative PCR has several advantages: (i) only a
small amount of DNA is needed for this assay and a large
number of samples can be analyzed simultaneously; (ii)
the results can be obtained quickly and submitted to sta-
tistical analysis (the use of replicates is needed to increase
the power assay); (iii) based on the ﬂuorescence appear-
ance during the exponential phase of the ampliﬁcation,
quantiﬁcation is also more accurate; (iv) real time PCR
assays obviate post-PCR manipulation preventing carry-
over contaminations; (v) the multiplex reduces the cost of
the analysis compared to a single-well assay [14]; and (vi)
whenreactionsarecarriedoutin384-wellplates,thereac-
tionvolumecanbereduced(15µL)decreasingthereagent
cost [5].
The rapid quantiﬁcation of the CYP2D6 copy num-
ber has become a signiﬁcant investment as regards the
large number of drugs metabolized by the CYP2D6 gene.
This new real-time quantitative PCR could be adapted
for high-throughput determination of CYP2D6 genotyp-
ing.
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